Rupa Mazumder | Toxicology and Pharmaceutical Science | Best Researcher Award

Best Researcher Award

Rupa Mazumder
Noida Institute of Engineering And Technology

Rupa Mazumder
Affiliation Noida Institute of Engineering And Technology
Country India
Scopus ID 7005832705
Documents 211
Citations 1,412
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0002-1888-548X

Rupa Mazumder is a researcher affiliated with the Noida Institute of Engineering And Technology, India, whose documented scholarly profile is associated with toxicology and pharmaceutical science. The supplied Scopus record reports 211 documents, 1,412 citations, and an h-index of 18, providing a bibliometric basis for considering the researcher within an academic recognition framework. [1]

Abstract

Rupa Mazumder is an India-based researcher affiliated with the Noida Institute of Engineering And Technology and associated with the subject area of Toxicology and Pharmaceutical Science. The supplied bibliometric profile records 211 scholarly documents, 1,412 citations, and an h-index of 18. These indicators provide measurable evidence of sustained research activity and scholarly visibility. Her profile is considered in relation to the Best Researcher Award under the International Invention Awards framework. Assessment of researcher recognition may consider publication productivity, citation influence, research continuity, subject expertise, and the broader relevance of scientific contributions. Bibliometric information should be interpreted alongside verified qualitative evidence and individual research outputs for balanced academic evaluation.

Keywords

Rupa Mazumder; Best Researcher Award; Toxicology; Pharmaceutical Science; Drug Research; Pharmacology; Research Impact; Scholarly Publications; Citation Analysis; h-index; Scientific Research; International Invention Awards.

Introduction

Researcher recognition in pharmaceutical and toxicological sciences commonly involves consideration of scholarly productivity, research quality, citation performance, and sustained engagement with scientific questions. Bibliometric indicators can provide a structured quantitative perspective, although they do not independently establish the originality or practical significance of individual studies. The available profile for Rupa Mazumder presents a substantial publication and citation record that can be examined as part of a broader academic assessment. [1] Standardized researcher identifiers such as Scopus Author ID and ORCID can also assist in distinguishing scholarly outputs and improving the reliability of attribution. [2]

Research Profile

The supplied profile identifies Rupa Mazumder with the Noida Institute of Engineering And Technology in India and places the research activity within Toxicology and Pharmaceutical Science. The reported Scopus Author ID is 7005832705, while the associated ORCID is 0000-0002-1888-548X. These persistent identifiers provide complementary mechanisms for connecting scholarly records with an individual researcher and can support verification across academic databases. [1] [2]

Research Contributions

Within toxicology and pharmaceutical science, research contributions may encompass the investigation of drug effects, safety, pharmacological mechanisms, toxicological responses, therapeutic development, and related biomedical questions. The available information does not provide a complete thematic inventory of Rupa Mazumder’s individual studies, so specific scientific claims should be based on verified publication records rather than inferred solely from bibliometric indicators. The documented publication volume nevertheless indicates sustained participation in scholarly research. [1]

Publications

The supplied Scopus information records 211 documents associated with the researcher profile. Publication counts are useful for describing research productivity but should be evaluated with attention to document type, authorship, journal quality, research field, chronology, and subject relevance. A complete publication assessment would require examination of the underlying indexed records and individual bibliographic metadata. The reported document count is therefore presented as a profile-level bibliometric indicator rather than as an independent measure of research quality. [1]

Research Impact

The supplied profile reports 1,412 citations and an h-index of 18. Citation indicators can help describe the visibility and scholarly uptake of published research, while the h-index combines productivity and citation dimensions into a single metric. Such measures vary across disciplines, career stages, database coverage, and publication practices and should therefore be interpreted within appropriate academic context. [1] Citation-based assessment is strongest when complemented by qualitative evidence concerning originality, methodological contribution, collaboration, and influence on subsequent research.

Award Suitability

The available bibliometric information provides a relevant quantitative foundation for consideration for the Best Researcher Award. The combination of 211 reported documents, 1,412 citations, and an h-index of 18 indicates an established scholarly record within the supplied profile. [1] Final award suitability should, however, be determined through verification of the researcher identity, publication record, research quality, originality, professional contributions, and alignment with the applicable award criteria. The profile therefore supports consideration without implying that bibliometric measures alone determine award outcome.

Conclusion

Rupa Mazumder’s supplied academic profile documents substantial scholarly activity in the field of Toxicology and Pharmaceutical Science, with 211 documents, 1,412 citations, and an h-index of 18. These indicators establish a useful quantitative basis for academic recognition while requiring contextual interpretation. [1] Verification through persistent researcher identifiers, indexed publications, and qualitative evidence can strengthen the assessment. On the information provided, the profile presents a credible basis for consideration under the Best Researcher Award category of the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rupa Mazumder, Author ID 7005832705. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005832705
  2. ORCID. (n.d.). ORCID record: Rupa Mazumder, ORCID 0000-0002-1888-548X. ORCID.
    https://orcid.org/0000-0002-1888-548X
  3. Journal article. (2026).Preparations, Applications, Patents, and Marketed Formulations of Nanoemulsions – A Comprehensive Review.
    http://dx.doi.org/10.2174/0122117385325186240912110731
  4. Journal article. (2025). A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease.
    https://doi.org/10.18311/jnr/2025/49903
  5. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/

Shiva Vairale | CSIR – National Chemical Laboratory | Best Researcher Award

Best Researcher Award

Shiva Vairale
CSIR – National chemical Laboratory

Shiva Vairale
Affiliation CSIR – National Chemical Laboratory
Country India
Scopus ID 60050407800
Documents 6
Citations 9
h-index 3
Subject Area Drug Discovery
Event International Invention Awards
Google Scholar Rgn4SCoAAAAJ

Shiva Vairale is a researcher affiliated with the CSIR – National Chemical Laboratory in India, with research interests associated with biochemical sciences and drug discovery. Publicly indexed research records connect his work with bioactive molecules, natural products, biological macromolecules, antimicrobial investigations, and pharmacological applications. His research activities include collaborative studies addressing biologically relevant compounds and their potential therapeutic significance. Available publication records identify contributions to peer-reviewed research involving sericin-based nanotherapeutics and insect-derived metabolites, illustrating an interdisciplinary orientation spanning biochemistry, pharmacology, and translational drug-discovery research. [1]

Abstract

Shiva Vairale is a researcher at CSIR – National Chemical Laboratory whose documented work focuses on biochemical sciences, natural bioactive compounds, and drug discovery. His research profile includes investigations of biologically active molecules, therapeutic mechanisms, antimicrobial activity, and emerging nanotherapeutic approaches. Published work has addressed sericin-based formulations for anti-urolithiatic and antibacterial applications, while a recent review examines insect-derived metabolites and their pharmacological potential in modern drug discovery. These studies reflect an interdisciplinary research direction connecting biochemistry, natural products, pharmacology, molecular mechanisms, and translational applications. His indexed research record provides measurable indicators of scholarly activity and citation-based visibility.

Keywords

Shiva Vairale, Best Researcher Award, drug discovery, biochemical sciences, natural products, insect-derived metabolites, pharmacology, bioactive compounds, sericin nanotherapeutics, antimicrobial research, therapeutic applications, CSIR-National Chemical Laboratory, India.

Introduction

Drug discovery increasingly integrates natural-product chemistry, molecular biology, pharmacology, and advanced formulation strategies to identify biologically useful compounds. Within this multidisciplinary landscape, Vairale’s documented research is associated with the investigation of bioactive substances and their therapeutic relevance. His work at CSIR-National Chemical Laboratory places these activities within an established Indian research environment focused on chemical and biological sciences. [2] Recent publications further demonstrate engagement with natural metabolites and biological macromolecules as potential sources of pharmacological applications. [3]

Research Profile

Vairale’s research profile is situated primarily within biochemical sciences and drug discovery. Publicly available institutional and bibliographic information associates him with the Biochemical Sciences Division of CSIR-National Chemical Laboratory and with research involving bioactive compounds, biological assays, natural metabolites, and therapeutic applications. His academic record also places his doctoral research within biological sciences, supporting an interdisciplinary trajectory connecting chemical and biological investigation. [2]

Research Contributions

A documented contribution involves research on sericin-based nanotherapeutics, examining sericin and related nanoparticle formulations for anti-urolithiatic and antibacterial applications. The study combines biological macromolecules, nanotechnology, characterization, and pharmacological assessment. [1] Another contribution is a review of insect-derived metabolites in drug discovery, covering chemically diverse metabolites and their biological mechanisms while considering their translational relevance to pharmacotherapy. [4]

Publications

Vairale has contributed to peer-reviewed publications spanning natural products, biological macromolecules, antimicrobial research, and drug discovery. A notable publication is Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications, published in the International Journal of Biological Macromolecules in 2025 with DOI 10.1016/j.ijbiomac.2025.146763. [1] His 2026 review, Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges, appeared in Pharmacological Research – Natural Products, DOI 10.1016/j.prenap.2026.100808. [4]

Research Impact

The research addresses scientific questions relevant to therapeutic discovery, particularly the identification and characterization of biologically active substances. Work on sericin-based systems explores potential applications against urolithiasis and bacterial activity, while research concerning insect metabolites considers their broader pharmacological potential. These themes are relevant to continuing efforts to identify new biological resources and mechanisms for therapeutic development. The supplied bibliometric profile records six documents, nine citations, and an h-index of three. [1]

Award Suitability

For recognition under a Best Researcher Award category, the documented record provides evidence of peer-reviewed research activity, interdisciplinary subject engagement, and identifiable contributions to drug-discovery research. Relevant evidence includes publications involving biological macromolecules and natural metabolites, collaboration across research groups, and indexed bibliometric indicators supplied for this profile. The award record should be considered alongside the complete nomination materials and applicable evaluation criteria of the International Invention Awards. [5]

Conclusion

Shiva Vairale’s documented research activity reflects an interdisciplinary focus on biochemical sciences and drug discovery, with published work addressing sericin-based nanotherapeutics and insect-derived metabolites. His research connects natural bioactive resources with pharmacological investigation and potential therapeutic applications. The available bibliometric information and publication record provide a structured basis for describing his scholarly profile and its relevance to research recognition within the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus Author Details: Author ID 60050407800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60050407800
  2. Review article. (2026). Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges.
    https://doi.org/10.1016/j.prenap.2026.100808
  3. Research article. (2025). Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications.
    https://doi.org/10.1016/j.ijbiomac.2025.146763
  4. Google Scholar. (n.d.). Google Scholar author profile: Shiva Vairale. Google Scholar.
    https://scholar.google.com/citations?hl=en&user=Rgn4SCoAAAAJ
  5. International Invention Awards. (2026). International Invention Award.
    https://inventionawards.org/

Stephen Chelko | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Stephen Chelko
Florida State University College of Medicine

Stephen Chelko
Affiliation Florida State University College of Medicine
Country United States
Scopus ID 54973874200
Documents 47
Citations 1,649
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0003-1675-5945

Stephen Chelko is a researcher affiliated with the Florida State University College of Medicine whose documented scholarly profile is associated with toxicology and pharmaceutical science. Available bibliometric information records 47 documents, 1,649 citations, and an h-index of 18, providing a quantitative basis for assessing research visibility and scholarly influence. [1]

Abstract

Stephen Chelko is a researcher associated with Florida State University College of Medicine and the fields of toxicology and pharmaceutical science. His indexed scholarly record comprises 47 documents, 1,649 citations, and an h-index of 18, according to the supplied Scopus profile information. These indicators provide a measurable basis for describing his research visibility and citation impact within scholarly databases. His profile may be considered in the context of recognition for innovative research, particularly where scientific investigation, translational relevance, and contribution to biomedical knowledge are central criteria. The Innovative Research Award provides a framework for highlighting documented scholarly achievement and research significance.

Keywords

Stephen Chelko; Innovative Research Award; toxicology; pharmaceutical science; biomedical research; Florida State University College of Medicine; research impact; scholarly publications; citation analysis; translational science.

Introduction

Academic recognition commonly considers the quality, relevance, originality, and influence of a researcher’s scholarly work. In this context, Stephen Chelko’s documented profile combines research activity in toxicology and pharmaceutical science with measurable bibliometric indicators. The available Scopus record identifies 47 documents, 1,649 citations, and an h-index of 18. [1]

Research Profile

Chelko’s stated subject area is Toxicology and Pharmaceutical Science, positioning his scholarly profile within disciplines concerned with biological effects, therapeutic development, pharmaceutical research, and related biomedical questions. His affiliation with Florida State University College of Medicine further places this work within an academic medical environment. [4]

Research Contributions

The available information supports describing Chelko’s contribution through his documented publication record and citation footprint rather than assigning unsupported claims about individual discoveries. Forty-seven indexed documents indicate sustained scholarly output, while the recorded citation count suggests that his published research has been referenced by subsequent academic literature. [1]

Publications

The supplied researcher profile reports 47 documents indexed in Scopus. Because complete publication titles, journals, publication years, and article-level DOI information were not supplied, this page does not attribute individual papers or DOI records without verification. The Scopus author profile provides the appropriate source for reviewing the complete indexed publication record. [1]

Research Impact

Research impact can be assessed through several complementary dimensions, including scholarly citations, publication continuity, disciplinary relevance, and potential contribution to scientific practice. Chelko’s reported 1,649 citations and h-index of 18 provide quantitative indicators of scholarly visibility, although bibliometric measures should be interpreted alongside qualitative assessment of research originality and significance. [1]

Award Suitability

The documented research profile is relevant to an Innovative Research Award because it demonstrates sustained scholarly activity in a biomedical subject area and a measurable citation record. Final award suitability should nevertheless depend on the official nomination criteria, verified publications, originality of contributions, supporting evidence, and independent evaluation by the responsible award committee. [5]

Conclusion

Stephen Chelko’s supplied academic profile presents a researcher working in toxicology and pharmaceutical science, affiliated with Florida State University College of Medicine. The reported record of 47 documents, 1,649 citations, and an h-index of 18 provides a measurable foundation for academic recognition. These indicators should be considered together with verified research quality and innovation.

References

  1. Elsevier. (n.d.). Scopus author details: Stephen Chelko, Author ID 54973874200. Scopus.
    https://www.scopus.com/pages/authors/54973874200
  2. ORCID. (n.d.). Stephen Chelko, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0003-1675-5945
  3. Google Scholar. (n.d.). Stephen Chelko β€” Google Scholar profile.
    https://scholar.google.com/citations?hl=en&user=5Hq6SM0AAAAJ
  4. Journal article. (2019.). Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.
    https://doi.org/10.1161/CIRCULATIONAHA.119.040676
  5. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

Ghazaleh Pouya | Pharmacology | Young Researcher Award

Ms. Ghazaleh Pouya | Pharmacology Science | Young Researcher Award

Ms. Ghazaleh Pouya | Sechenov University | Russia

Ms. Ghazaleh Pouya is an aspiring pharmaceutical scientist and multidisciplinary researcher, currently pursuing a Master’s degree in Biology at Sechenov University with a focus on Innovative Medicines. With a Doctor of Pharmacy (Pharm.D.) degree from the same university, she integrates her clinical pharmaceutical knowledge with advanced research in transdermal drug delivery and AI-powered biomedical solutions. As a lab assistant and assistant researcher, she actively contributes to academic publications, interdisciplinary projects, and data analytics in pharma-biotech. Her curiosity and dedication to translational medicine, wound healing systems, and personalized therapeutics reflect in her dynamic academic and research involvement, positioning her as a promising young innovator at the intersection of pharmacy, biology, and artificial intelligence.

Profile

ORCID

Education

Ms. Ghazaleh earned her Pharm.D. from Sechenov University, completing a thesis on in-vitro modeling of aero-dispersed film-forming systems. Currently, she is enrolled in a Master’s program in Biology, focusing on Innovative Medicines, at the same institution. In parallel, she undertakes applied IT training at School-21, a program dedicated to programming, app development, and clinical data analysis in medicine. Her multidisciplinary training bridges biological sciences, medical informatics, and pharmaceutical technologies. Ms. Ghazaleh’s strong academic background provides her with a unique perspective in drug delivery development and biomedical computation, preparing her for impactful contributions to pharmaceutical innovation and AI-assisted healthcare systems.

Experience

Ms. Ghazaleh Pouya is a laboratory assistant and student researcher at Sechenov University, actively involved in both experimental design and data analysis across pharmaceutical and biological domains, where she develops tools for clinical and pharmaceutical data evaluation. She collaborates with the Department of Pharmaceutical Technology, Department of Biology (Innovative Drugs), and the PHARMA-PREMIUM Scientific Research Center, contributing to a range of wound treatment, drug delivery, and AI-modeling projects. This diverse experience strengthens her competence in translational science, combining wet lab experimentation with computational modeling, ensuring real-world applicability of research findings.

Research Interests

Ms. Ghazaleh’s research focuses on transdermal drug delivery systems, pharmaceutical nanocarriers, and AI-integrated biomedical analytics. She is also exploring in vitro skin models, pharmacogenomics, and quality-by-design (QbD) strategies in formulation development. Her innovative mindset drives her to investigate how machine learning can optimize personalized drug delivery mechanisms, especially for wound treatment and skin permeability. She works on enhancing the bioavailability and targeted release of active substances using nano-based platforms, contributing to the next generation of smart drug delivery systems. Ghazaleh’s vision blends biological sciences, digital health, and pharmaceutical technology for patient-centered therapeutic innovations.

Award

Ms. Ghazaleh Pouya is a strong candidate for the “Young Researcher Award” under the International Invention Awards 2025. Her multidisciplinary background, three completed co-authored publications, ongoing research in pharmaceutical aerosols, and AI-driven drug delivery platforms reflect her impactful contributions at an early stage of her career. Her experience across pharmaceutical formulation, lab analytics, and computational modeling positions her among the emerging leaders in pharm-biotech research. Her self-driven participation in interdepartmental and interdisciplinary collaborations exemplifies the qualities of a future research innovator. This award would not only recognize her current achievements but also catalyze her continued excellence in translational research.

Publications

Transdermal Drug Delivery Systems: Methods for Enhancing Skin Permeability and Their Evaluation

Development of water vapor permeability determination methodology for spray film-forming systems

characterization and screening parameters of spray film-forming systems: a comprehensive study on dosage forms and quality indicators

Conclusion

Ms. Ghazaleh Pouya embodies the ideal profile of a rising biomedical innovator, integrating academic rigor, hands-on laboratory experience, and computational skills into a cohesive research journey. Her contributions to pharmaceutical sciences, particularly in film-forming drug systems and skin permeability, along with her novel integration of AI in drug delivery, showcase her potential to advance therapeutic design. With publications in reputable journals, active institutional collaborations, and an interdisciplinary mindset, she has already laid a strong foundation for a successful career in science and innovation. Recognition through the Young Researcher Award will further encourage her to expand her scientific impact and pursue future breakthroughs in personalized medicine and nanopharmaceuticals.

Kyle Frey | Pharmaceutical Manufacturing | Best Researcher Award

Mr.Kyle Frey | Pharmaceutical Manufacturing | Best Researcher Award

Quotient Sciences, United StatesΒ 

Profile

orcid

πŸŽ“ Early Academic Pursuits

Kyle A. Frey began his scientific journey with a rigorous academic foundation that included two years of medical school training at Thomas Jefferson Medical College. This early exposure to the intricacies of clinical medicine uniquely positioned him with an interdisciplinary understanding of pharmaceutical sciences, bridging the gap between patient care and drug development. His academic experiences fueled his desire to pivot toward formulation science, where he could more directly impact drug performance and patient outcomes.

πŸ§ͺ Professional Endeavors

Currently serving as Formulation Scientist III at Quotient Sciences in Wilmington, DE, Kyle has amassed over 12 years of cumulative experience in pharmaceutical sciences. He leads end-to-end drug development projects, starting from initial drug substance characterization and preformulation assessment to formulation design, scale-up, and GMP manufacturing for clinical trials. Known for his independent thinking and technical versatility, Kyle excels in resolving complex formulation challenges and optimizing products for scalability and commercialization.

πŸ“š Contributions and Research Focus

Kyle’s research has consistently pushed the boundaries of pharmaceutical innovation. His focus on novel drug delivery systems, solid and liquid oral formulations, and low-dose mixing technologies has earned him international recognition. His groundbreaking work in resonant acoustic mixing (RAM) was showcased at AAPS PharmSci 360 in 2023, positioning him at the forefront of low-dose blending technologies. His hands-on use and thought leadership in ASAPprimeβ„’ accelerated stability testing further highlight his contributions to long-term formulation stability and predictive modeling.

🌍 Impact and Influence

A recognized thought leader, Kyle was provisionally selected for the β€œBest Researcher Award” in the International Top Pharmaceutical Awards and listed in Marquis Who’s Who 2024 as one of America’s Distinguished Scientists. These honors reflect not only the depth of his technical expertise but also his influence within the global pharmaceutical community. His work directly supports translational pharmaceutics-based clinical trials, impacting real-world therapeutic delivery.

πŸ”¬ Academic Citations and Publications

Kyle’s innovative research is documented in top-tier journals, with recent publications in Pharmaceutical Research (2023) and the International Journal of Pharmaceutics (2025). He is also registered with ORCID (0000-0003-1361-4960) and holds a Web of Science Researcher ID (LXA-8444-2024), ensuring his contributions are accessible and citable by academics and professionals alike.

🧰 Technical Skills and Expertise

Kyle is proficient in a wide array of analytical and formulation equipment and techniques. His expertise spans thermal (DSC, MDSC, TGA), chromatographic and spectroscopic (HPLC, UPLC, GC, FTIR), and physical testing (SEM, Karl Fischer, laser diffraction, density measurements). Additionally, his deep understanding of solid and liquid formulation equipment, including Korsch automated presses, spray dryers, and functional coaters, makes him a go-to SME for development and scale-up.

πŸ‘¨β€πŸ« Teaching and Mentorship

An enthusiastic mentor and patient teacher, Kyle is dedicated to cultivating the next generation of scientists. He regularly mentors junior scientists, providing training on both laboratory techniques and critical thinking skills. His strong communication abilities and engaging presentation style have also made him a well-received speaker and educator, both within his organization and at scientific conferences.

🧭 Legacy and Future Contributions

Kyle’s journey is far from over. With a strong drive for innovation and a proven record of solving complex formulation problems, he continues to envision a future where drug development is smarter, faster, and more patient-centered. His lifelong commitment to learning, along with his desire to make impactful contributions to science and society, positions him as a rising luminary in pharmaceutical formulation and manufacturing.

πŸ“šΒ Publication

  • Title: Sample Preparation Techniques to Enhance Uniformity of Low-Dose Blends Mixed by Resonant Acoustic Mixing Technology
    Authors: Frey, K.A., Baker, H., Purcell, D.K., Lewis, A.L.
    Journal: International Journal of Pharmaceutics
    Year: 2025

  • Title: Use of Resonant Acoustic Mixing Technology for Ultra-Low-Dose Blending in a Single-Step Mixing Process (Poster Presentation)
    Authors: Frey, K.A., Baker, H., Purcell, D.K., Lewis, A.L., Engers, D.A.
    Journal/Conference: AAPS PharmSci 360
    Year: 2023
    Poster ID: M1230-11-79

  • Title: Use of Resonant Acoustic Mixing Technology for Ultra-Low-Dose Blending in a Single-Step Mixing Process
    Authors: Frey, K.A., Baker, H., Purcell, D.K., Lewis, A.L., Engers, D.A.
    Journal: Pharmaceutical Research
    Year: 2023
    Citations: Web of Science (4), CrossRef (5), Google Scholar (7)

  • Title: Sample Preparation Techniques to Enhance Uniformity of Low-Dose Blends Mixed by Resonant Acoustic Mixing Technology (Pre-print)
    Authors: Frey, K.A., Baker, H., Purcell, D.K., Lewis, A.L.
    Platform: SSRN Pre-Print, International Journal of Pharmaceutics
    Year: 2025

 

Assoc. Prof. Dr. Yousef Bin Jardan | Pharmaceutical Sciences | Best Researcher Award

Assoc. Prof. Dr. Yousef Bin Jardan | Pharmaceutical Sciences | Best Researcher Award

King Saud University, Saudi Arabia.

Yousef Abdullah M. Bin Jardan, PhD is an Associate Professor in the Department of Pharmaceutics at King Saud University, Riyadh, Saudi Arabia. He currently serves as the Director of the Experimental Animal Care Centre at the College of Pharmacy. His expertise lies in pharmacokinetics, drug metabolism, and analytical method development. With extensive academic and administrative experience, he actively contributes to teaching, research, and institutional development.

Profile

Scopus
Orcid

πŸŽ“ Education

Assoc. Prof. Dr. Yousef Bin Jardan holds a Ph.D. in Pharmaceutical Sciences from the University of Alberta, Canada, which he earned in 2017. He previously obtained his B.Sc. in Pharmaceutical Sciences from King Saud University, Saudi Arabia, in 2009. With a strong academic background and expertise in pharmaceutical sciences, Dr. Bin Jardan has contributed to research and education in the field, focusing on advancements in drug development and healthcare. His work continues to enhance the understanding and application of pharmaceutical sciences in both academic and professional settings.

πŸŽ“ Academic Positions

Assoc. Prof. Dr. Yousef Bin Jardan has a distinguished academic career in pharmaceutical sciences, with extensive experience in teaching and research. Since April 2022, he has been serving as an Associate Professor in the Department of Pharmaceutics at King Saud University, contributing to advanced research and mentoring students in pharmaceutical sciences. Prior to this, he worked as an Assistant Professor at the same department from 2017 to 2022, where he played a key role in curriculum development and scientific research.

Before joining King Saud University as a faculty member, Dr. Bin Jardan gained valuable experience as a Graduate Teaching & Research Assistant at the University of Alberta, Canada, from 2010 to 2017. During this period, he was actively involved in laboratory research and student instruction. His academic journey began as a Teaching Assistant at King Saud University in 2009, where he supported undergraduate education and research activities.

πŸ‘¨β€πŸ« Teaching Experience

Assoc. Prof. Dr. Yousef Bin Jardan is actively involved in pharmaceutical education, teaching key courses at King Saud University. He instructs Pharmaceutical Calculations (PHT 210 – PharmD), equipping students with essential mathematical skills for accurate drug formulation and dosing. Additionally, he teaches Biopharmaceutics (PHT 414 – B.Pharm & PHT 417 – PharmD), focusing on drug absorption, distribution, metabolism, and elimination, crucial for understanding drug efficacy and safety. He also oversees Internship Training (PHTR 211 – PharmD), guiding students through practical experiences in clinical and pharmaceutical settings. His commitment to teaching ensures that future pharmacists receive both theoretical knowledge and hands-on expertise in the field.

🏒 Administrative Roles

Assoc. Prof. Dr. Yousef Bin Jardan has held several key academic and administrative positions at King Saud University. Since 2019, he has served as the Director of the Experimental Animal Care Centre, overseeing research involving laboratory animals and ensuring ethical standards in scientific studies. Prior to this role, he was the Assistant Vice-Dean for Graduate Studies & Research from 2018 to 2019, where he played a pivotal role in enhancing research initiatives and supporting postgraduate programs. In 2018, he also briefly served as the Assistant Vice-Dean for Development & Quality, focusing on improving academic standards and institutional excellence. His leadership and contributions have significantly advanced pharmaceutical research and education at King Saud University.

πŸ›οΈ Council & Committee Memberships

Pharmaceutics Department Council Member – (2017–Present)

Academic Committee Member – College of Pharmacy (2017–2018)

Annual Research Day Committee Member – (2017–2018)

πŸ”¬ Research Interests

Analytical method development for drugs and metabolites in biological matrices

Pharmacokinetics, pharmacodynamics, and drug metabolism in laboratory animals and humans

Drug-disease interactions using in vivo models

πŸ† Awards & Recognitions

Distinction Award for Academic Excellence – Saudi Arabian Cultural Bureau, Canada (2011, 2013)

Graduate Student Award – University of Alberta (2014)

Graduate Students' Association Academic Travel Award – University of Alberta (2015, 2016)

CSPS Meeting Travel Award – Faculty of Pharmacy, University of Alberta (2015, 2016)

πŸŽ“ Licenses & Certifications

Licensed Pharmacist – Saudi Commission for Health Specialties (SCFHS) (2010–Present)

πŸ“œ Notable Publications

Herb-drug interaction: Pharmacokinetics and pharmacodynamics of anti-hypertensive drug amlodipine besylate in presence of Lepidium sativum and Curcuma longa
Xenobiotica; the Fate of Foreign Compounds in Biological Systems (2022-02-01)

Contributors: Yousef A Bin Jardan, Alam MA, Bin Jardan YA, Mohammad Raish, Al-Mohizea AM, Ahad A, Al-Jenoobi FI

Deciphering chemical profiling, pharmacological responses, and potential bioactive constituents of Saussurea lappa Decne. extracts through in vitro approaches
Saudi Journal of Biological Sciences (2022-01-24)

Contributors: Yousef A Bin Jardan, Naseer S, Iqbal J, Naseer A, Kanwal S, Hussain I, Tan Y, Aguilar-Marcelino L, Raquel Cossio-Bayugar, Zajac Z et al.

Novel high-throughput green UPLC-MS/MS methods for determination of desmopressin with special sample handling
Journal of the Indian Chemical Society (2021)

Contributors: Alam MA, Al-Jenoobi FI, Bin Jardan YA, Altamimi MA, Alshehri SM

Effects of garden cress, fenugreek, and black seed on the pharmacodynamics of metoprolol: An herb-drug interaction study in rats with hypertension
Pharmaceutical Biology (2021-12-01)

Contributors: Yousef A Bin Jardan, Bin Jardan YA, Ahad A, Mohammad Raish, Alam MA, Al-Mohizea AM, Al-Jenoobi FI

Eudragit-coated sporopollenin exine microcapsules (SEMC) of Phoenix dactylifera L. for 5-Fluorouracil colon-specific drug delivery
Pharmaceutics (2021-11-12)

Contributors: Yousef A Bin Jardan, Mohammad Raish, Dr. Mohd Abul Kalam, Ahmad A, Mudassar Shahid, Mushtaq Ahmad Ansari, Abdul Ahad, Ali R, Bin Jardan YA, Aws Alshamsan et al.

 

 

Dr. Jad El Masri | Medical Research | Young Scientist Award

Dr. Jad El Masri | Medical Research | Young Scientist Award

American University of Beirut, Lebanon.

Dr. Jad El Masri is a postdoctoral research fellow at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. With a strong background in clinical research, pathology, and neuroscience, he has contributed significantly to oncology, epidemiology, and neurosurgery. Holding an MD and multiple master’s degrees, he is set to complete his PhD in Clinical Research and Pathology in 2025. With over 45 completed research projects and 43 publications, Dr. El Masri has been recognized for his work in cancer biomarkers, epidemiological risk factors, and computational biology.

Profile

Google Scholar

πŸŽ“ Education

Dr. Jad El Masri has a diverse academic background spanning clinical research, pathology, neuroscience, and medical sciences. He is currently completing his PhD in Clinical Research & Pathology at UniversitΓ© Paris-Est (2022–2025) while holding multiple master’s degrees in Human Morphology, Clinical Investigation, and Neuroscience from leading institutions, including the American University of Beirut and Lebanese University. In addition, he earned his Medical Degree (MD) from Lebanese University (2018–2024) and holds a Biochemistry License Degree (2017–2020). His academic journey began with a French Baccalaureate in Science from Rawdat Fayhaa Secondary School (2001–2016).

πŸ’Ό Experience

Dr. Jad El Masri is currently a Postdoctoral Research Fellow at the Broad Institute of MIT & Harvard (2025–Present) and Dana-Farber Cancer Institute (2024–Present), where he focuses on oncology and computational biology. His clinical experience includes multiple internships across hospitals in Lebanon and Germany (2022–2024), gaining hands-on expertise in various medical disciplines. Additionally, he completed elective neurosurgery rotations at the American University of Beirut Medical Center (AUBMC) and Medizinische Hochschule Hannover, further strengthening his specialization in neurosurgery and brain cancer research.

πŸ”¬ Research Interests

Oncology – Brain cancer, genetic biomarkers, metastasis

Epidemiology – Risk factors, diet effects, environmental exposure

Neurosurgery – Computational biology, single-cell DNA sequencing

πŸ† Awards & Recognitions

Young Scientist Award – Recognized for contributions to neuroscience research

Editorial Board Member – Journal of Public Health Research

Professional Memberships – European Stroke Organization, Congress of Neurological Surgeons

πŸ“š Selected Publications

1️⃣ Social media medical misinformation: Impact on mental health and vaccination decision among university students
πŸ“– Irish Journal of Medical Science (1971-), 192(1), 291-301 (2023)
πŸ“„ DOI | Cited by: 34

2️⃣ Menstrual abnormalities post-COVID vaccination: A cross-sectional study on adult Lebanese women
πŸ“– Irish Journal of Medical Science (1971-), 192(3), 1163-1170 (2023)
πŸ“„ DOI | Cited by: 27

3️⃣ Contribution of Arab world in transplant research: A PubMed-based bibliometric analysis
πŸ“– Transplant Immunology, 101432 (2021)
πŸ“„ DOI | Cited by: 23

4️⃣ Cancer research activity in the Arab world: A 15-year bibliometric analysis
πŸ“– Journal of the Egyptian Public Health Association, 97(1), 26 (2022)
πŸ“„ DOI | Cited by: 22

5️⃣ Contribution of Arab countries to familial Mediterranean fever research: A PubMed-based bibliometric analysis
πŸ“– Rheumatology International, 42(1), 95-100 (2022)
πŸ“„ DOI | Cited by: 22